Karyopharm Therap(KPTI.US)

Last Updated 19:00:00 ET
longbridge loading

Karyopharm (KPTI) Leans on SENTRY in Pivotal Call

Tip Ranks·
US
KPTI
+2.76%
US
IHE
+1.08%
US
XBI
+1.02%
Tip Ranks·
US
KPTI
+2.76%
US
IHE
+1.08%
US
XBI
+1.02%

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga_article·
US
WOK
-19.47%
US
MTVA
-3.29%
US
VRAX
-5.52%
benzinga_article·
US
WOK
-19.47%
US
MTVA
-3.29%
US
VRAX
-5.52%

Karyopharm Therapeutics shares are trading lower. The company reported its Q1 financial results.

benzinga_article·
US
KPTI
+2.76%
US
FBT
+0.74%
US
IHE
+1.08%
benzinga_article·
US
KPTI
+2.76%
US
FBT
+0.74%
US
IHE
+1.08%

RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)

Tip Ranks·
US
KPTI
+2.76%
US
IBB
+0.82%
US
BIB
+0.08%
Tip Ranks·
US
KPTI
+2.76%
US
IBB
+0.82%
US
BIB
+0.08%

Karyopharm Therapeutics Inc. Stock 12‑Month Price Target Raised to $15, Implies 69% Upside

TradingView·
US
KPTI
+2.76%
TradingView·
US
KPTI
+2.76%

Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript

benzinga_article·
US
KPTI
+2.76%
US
VHT
+0.73%
US
PBE
+0.50%
benzinga_article·
US
KPTI
+2.76%
US
VHT
+0.73%
US
PBE
+0.50%

Karyopharm Therapeutics Inc. 1Q 2026: Revenue $35.1M, EPS $(1.24) — 10-Q Summary

TradingView·
US
KPTI
+2.76%
US
XBI
+1.02%
US
XLV
+0.72%
TradingView·
US
KPTI
+2.76%
US
XBI
+1.02%
US
XLV
+0.72%

Karyopharm Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 35.07 M

Earnings Watch·
US
KPTI
+2.76%
Earnings Watch·
US
KPTI
+2.76%

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | KPTI Stock News

StockTitan·
US
KPTI
+2.76%
US
XLV
+0.72%
US
SBIO
+1.82%
StockTitan·
US
KPTI
+2.76%
US
XLV
+0.72%
US
SBIO
+1.82%
© 2026 Longbridge｜Disclaimer